CLAIM AMENDMENTS

3. (Amended) An isolated cancer peptide consisting ~~essentially~~ of a portion of SEQ ID NO: 4, wherein the portion comprises (i) amino acids 55-62 of SEQ ID NO: 4 or (ii) amino acids 127-136 of SEQ ID NO: 4, or a functionally equivalent variant thereof, wherein the functionally equivalent variant has at least 85% sequence homology with the cancer peptide, wherein said cancer peptide or functionally equivalent variant is immunologically recognized by antigen specific cytotoxic T lymphocytes, wherein said antigen is an epitope of a protein having the amino acid sequence of SEQ ID NO: 4, wherein said cancer peptide is about 10 amino acids in length and optionally further consists of 1 to about 10 amino acids at the N-terminus of the cancer peptide.

5. (Amended) The isolated cancer peptide of claim 3, wherein the cytotoxic T lymphocytes are restricted by a Major Histocompatibility Complex (MHC) molecule.

6. (Amended) The isolated cancer peptide of claim 5, wherein the MHC molecule is an MHC class I molecule.

7. (Amended) The isolated cancer peptide of claim 3, wherein the cancer peptide is derived from a cancer selected from the group consisting of: a non-Hodgkins lymphoma, leukemia, Hodgkins lymphoma, lung cancer, liver cancer, metastases, melanoma, adenocarcinoma, thymoma, colon cancer, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer and sarcoma.

8. (Amended) The isolated cancer peptide of claim 3, wherein the isolated cancer peptide is presented by a primary breast tumor cell or by a melanoma cell.

10. (Amended) The isolated cancer peptide of claim 3, wherein the isolated cancer peptide consists ~~essentially~~ of amino acids 53-62 of SEQ ID NO: 4.

11. (Cancelled)

12. (Amended) The isolated cancer peptide of claim 3, further consisting ~~essentially~~ of 1 to about 5 amino acids at the N-terminus of the cancer peptide.

3 7-10-04 Do not enter